Study on the Utilization of Cabozantinib in Adult Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC) in 2nd Line Treatment Following Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy Under Real-real Life Clinical Setting in France.

Inclusion Criteria

• •Male or female ≥ 18 age at the time of cabozantinib initiation
• •Pathologically confirmed diagnosis of Renal Cell Carcinoma (Clear Cell or non-Clear Cell) cancer considered as advanced or metastatic at the time of cabozantinib initiation
• •Intention to be treated with cabozantinib tablets according to the current local Summary of Product Characteristics (SmPC) (France)
• •Initiating cabozantinib as a second line of treatment (Baseline visit must be performed before cabozantinib first intake)